Jason Hall, MD
Ophthalmology · Manchester, NHNPI 1033378831
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alcon at 37.4% of the total.
Across 53 payments — averaging $34.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$685
- AbbVie$411
- Bausch & Lomb Americas Inc.$262
- Glaukos Corporation$141
- Aerie Pharmaceuticals, Inc.$131
- Sight Sciences, Inc.$55
- plus $148 from 6 others
Across 3 payments — averaging $4133.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$12K
What the payments were for
- Food & beverage$1,825100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 21 | $685 |
| AbbVie(2 entities) | 12 | $411 |
| Bausch & Lomb Americas Inc. | 6 | $262 |
| Glaukos Corporation | 2 | $141 |
| Aerie Pharmaceuticals, Inc. | 2 | $131 |
| Sight Sciences, Inc. | 3 | $55 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 1 | $33 |
| Johnson & Johnson | 1 | $25 |
| Thea Pharma Inc. | 1 | $16 |
| NEW World Medical,inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$300
- XEN GLAUCOMA TREATMENT SYSTEM$223
- Rhopressa$219
- Rocklatan$219
- enVista Aspire IOL$150
- iDose$107
How this compares
$1,833 in reported general payments places this provider in the 60th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 126 | $78,980 |
| LumiganBimatoprost | 110 | $67,326 |
| RhopressaNetarsudil Mesylate | 49 | $31,482 |
| CombiganBrimonidine Tartrate/Timolol | 83 | $31,265 |
| RestasisCyclosporine | 32 | $26,650 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 125 | $16,389 |
| Latanoprost | 1,174 | $10,675 |
| Travoprost | 72 | $9,625 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $8,720 |
| Cyclosporine | 11 | $7,741 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 381 | $5,983 |
| Prednisolone Acetate | 118 | $5,616 |
| Brimonidine Tartrate | 216 | $4,536 |
| Brinzolamide | 25 | $3,856 |
| Timolol Maleate | 269 | $2,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $411 | $125,240225 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $131 | $110,462175 claims |
| AlconSimbrinza | $685 | $8,72031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Manchester
- Ahad FazelatManchester$8K
- Vasilios LazosManchester$4K
- Maxwell EliaManchester$3K
- Amy HennessyManchester$3K
- Sara BozorgManchester$3K
- Lola GrilloManchester$2K
- Anthony CorrentiManchester$849
- Nancy Efferson BonacheaManchester$737
- Kimberly LicciardiManchester$571
- Christiana MunroeManchester$372
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.